Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29837993 | 1.00 | KIF11 (0.45) | KIF11RXRARXRGXDHTAS2R14 | |
| SCHEMBL25983036 | 0.86 | KIF11 (0.52) | KIF11RXRARXRGXDHTAS2R14 | |
| SCHEMBL1334073 | 0.86 | KIF11 (0.52) | KIF11RXRARXRGXDHTAS2R14 | |
| SCHEMBL11966001 | 0.81 | KIF11 (0.44) | KIF11GRM5 | |
| SCHEMBL16952351 | 0.78 | RXRA (0.33) | RXRARXRG | |
| SCHEMBL2139979 | 0.78 | RXRA (0.37) | RXRARXRGVNN1 | |
| SCHEMBL16960871 | 0.78 | GRM5 (0.35) | RXRARXRGGRM5 | |
| SCHEMBL1421650 | 0.78 | GRM5 (0.47) | GRM5 | |
| SCHEMBL56741 | 0.78 | GRM5 (0.43) | GRM5 | |
| SCHEMBL16894099 | 0.77 | KIF11 (0.65) | KIF11RXRARXRGGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| EP-3887359-B1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | UNIV COPENHAGEN (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20260062391-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12291508-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240279188-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| WO-2024024508-A1 | COMPOSITION, FILM, OPTICAL FILTER, SOLID STATE IMAGING DEVICE, IMAGE DISPLAY DEVICE, INFRARED RADIATION SENSOR, AND METHOD FOR PRODUCING CAMERA MODULE | 富士フイルム株式会社 | 2024-02-01 | — | — | WO | disclosed |
| CN-117229268-A | Hydrazide-containing nuclear transport modulators and uses thereof | 卡尔约药物治疗公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117203206-A | GCN2 modulating compounds and uses thereof | 希伯塞尔股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2005-05-19 | — | — | US | disclosed |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1438302-A1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR AGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-07-21 | — | — | EP | disclosed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004026822-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003029233-A1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR AGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | KIF11 4245/4885RXRA 2353/4885RXRG 1540/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | KIF11 3432/4885RXRA 3069/4885RXRG 2259/4885 |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | KIF11 3432/4885RXRA 3069/4885RXRG 2259/4885 |
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | SLC6A3, DRD3, GPR3 | KIF11 1422/4885RXRA 971/4885RXRG 1031/4885 |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | KIF11 4245/4885RXRA 2353/4885RXRG 1540/4885 |
| US-20260062391-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | SLC8A1, SLC9A1, SLC8B1 | KIF11 1161/4885RXRA 2532/4885RXRG 2614/4885 |
| US-20240279188-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, KPNA1, ABCB11 | KIF11 1774/4885RXRA 1802/4885RXRG 1958/4885 |
| US-12291508-B2 | Hydrazide containing nuclear transport modulators and uses thereof | XPO1, KPNA1, ABCB11 | KIF11 1774/4885RXRA 1802/4885RXRG 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.